日本骨质疏松症或骨质减少男性及骨折临床风险因素患者四年阿仑膦酸盐治疗经验[撤回]

Experience with Alendronate Treatment for Four Years among Japanese Men with Osteoporosis or Osteopenia and Clinical Risk Factors for Fractures [Retraction].

出版信息

Ther Clin Risk Manag. 2022 Aug 10;18:785-786. doi: 10.2147/TCRM.S385426. eCollection 2022.

DOI:10.2147/TCRM.S385426

PMID:35975129

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9375997/

Abstract

[This retracts the article DOI: 10.2147/TCRM.S15812.].

摘要

[本文撤回文章DOI: 10.2147/TCRM.S15812。]

相似文献

Experience with Alendronate Treatment for Four Years among Japanese Men with Osteoporosis or Osteopenia and Clinical Risk Factors for Fractures [Retraction].日本骨质疏松症或骨质减少男性及骨折临床风险因素患者四年阿仑膦酸盐治疗经验[撤回]

Ther Clin Risk Manag. 2022 Aug 10;18:785-786. doi: 10.2147/TCRM.S385426. eCollection 2022.

Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.日本骨质疏松或骨量减少症伴有骨折临床风险因素的男性患者使用阿伦膦酸盐治疗四年的经验。

Ther Clin Risk Manag. 2010 Dec 6;6:593-600. doi: 10.2147/TCRM.S15812.

Erratum: Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures [Expression of concern].

Ther Clin Risk Manag. 2018 Oct 30;14:2137. doi: 10.2147/TCRM.S192185. eCollection 2018.

Editorial Expression of Concern: Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Clin Rheumatol. 2021 Aug;40(8):3387. doi: 10.1007/s10067-021-05796-3.

A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.钙和维生素D补充剂、依替膦酸二钠和阿仑膦酸钠预防接受糖皮质激素治疗女性椎体骨折的成本效益分析。

J Rheumatol. 2003 Jan;30(1):132-8.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.双膦酸盐用于预防和治疗骨质疏松症的成本效益：文献的结构化综述

Pharmacoeconomics. 2007;25(11):913-33. doi: 10.2165/00019053-200725110-00003.

Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.在日本实施糖皮质激素性骨质疏松症治疗指南的成本效益分析。

Osteoporos Int. 2019 Feb;30(2):299-310. doi: 10.1007/s00198-018-4798-9. Epub 2019 Jan 4.

Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.用于治疗老年日本女性脆性骨折高危人群骨质疏松症药物的成本效果分析：地舒单抗与每周阿仑膦酸钠的比较。

Arch Osteoporos. 2018 Aug 29;13(1):94. doi: 10.1007/s11657-018-0509-6.

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.阿仑膦酸钠联合阿尔法骨化醇治疗骨折高风险骨质疏松症患者的效果：日本骨质疏松症干预试验（JOINT）-02。

Curr Med Res Opin. 2011 Jun;27(6):1273-84. doi: 10.1185/03007995.2011.580341. Epub 2011 May 10.

Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.长期药物治疗和药物停药及停药期用于预防骨质疏松性骨折：系统评价。

Ann Intern Med. 2019 Jul 2;171(1):37-50. doi: 10.7326/M19-0533. Epub 2019 Apr 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

日本骨质疏松症或骨质减少男性及骨折临床风险因素患者四年阿仑膦酸盐治疗经验[撤回]

Experience with Alendronate Treatment for Four Years among Japanese Men with Osteoporosis or Osteopenia and Clinical Risk Factors for Fractures [Retraction].

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献